MonTa Biosciences successfully dose first patient in phase I clinical trial

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]

MonTa Biosciences awarded approval from regulatory agencies to start phase I study

MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]

MonTa Biosciences becomes a Clinical Stage Company

MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]

MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program

MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]

MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency

MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]

MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development

Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]

MonTa Biosciences close a Series A investment from existing investors to complete phase I in cancer patients

MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps [...]

Selected as an alumni case in the Nordic Mentoring Programme

MonTa Biosceinces was selected among successful biotech startups in the Nordic Mentoring Programme as an [...]

Attending the BioEurope conference in Hamburg

MonTa Biosciences is attending the BioEurope conference in Hamburg to meet with biotech and pharma companies [...]

Presenting data at the cancer immunotherapy SITC conference

MonTa Biosciences is attending the cancer immunotherapy SITC conference in Washington DC to present data on our [...]

Meeting with Key Opinion Leaders to plan phase I trial in patients

MonTa Biosciences attends the ESMO conference in Barcelona to meet with Key Opinion Leaders to [...]

Fireside interview at the IP-FAIR conference

MonTa Biosciences is invited to a fireside interview at the IP-FAIR conference in Copenhagen on May 8. [...]

Pharma business conference BioEurope in Vienna

MonTa Biosciences join the pharma business conference BioEurope in Vienna to meet with pharma and biotech [...]

Investment with Consolidated Holdings

MonTa Biosciences closes investment with Consolidated Holdings to secure future development towards clinical trials. Link [...]

Invitation to speak and join panel discussion at the NLSDays

MonTa Biosciences is invited to speak and join panel discussion with major Big Pharma companies Roche [...]

MonTa Biosciences attend Bio in Boston

MonTa Biosciences attend Bio in Boston from June 4-7th to meet and discuss partnership, collaborations and investment opportunities. Send [...]

The AngloNordic Life science conference

MonTa Biosciences attend the AngloNordic Life science conference in London on Mya 24th to meet investors and network [...]

Attending the Biotechandmoney conference

MonTa Biosciences attend the Biotechandmoney conference in London on February 5-6. [...]

BioEurope partnering conference in Berlin

MonTa Biosciences attends the BioEurope partnering conference in Berlin from November 4-8. Please book a meeting with [...]

Completion of license agreements

MonTa Biosciences announces completion of license agreements with UC San Diego and Danish Technical University. The immune [...]